Joshua Schafer Sells 10,500 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) EVP Joshua Schafer sold 10,500 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the sale, the executive vice president now owns 29,486 shares in the company, valued at $231,759.96. This trade represents a 26.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $8.07 on Friday. The stock’s 50-day moving average is $8.22 and its 200 day moving average is $8.06. The stock has a market cap of $430.78 million, a price-to-earnings ratio of -4.10 and a beta of 2.00. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Canaccord Genuity Group decreased their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics has a consensus rating of “Buy” and an average target price of $21.57.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC increased its holdings in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after buying an additional 5,940 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Zevra Therapeutics during the 4th quarter worth approximately $94,000. Hunter Associates Investment Management LLC purchased a new position in Zevra Therapeutics in the 3rd quarter worth approximately $92,000. XTX Topco Ltd purchased a new position in Zevra Therapeutics in the 3rd quarter worth approximately $94,000. Finally, Intech Investment Management LLC bought a new stake in Zevra Therapeutics in the third quarter valued at approximately $95,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.